Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis

被引：0
|
作者：
Machaon M Bonafede
Anupama Kalsekar
Manjiri Pawaskar
Kimberly M Ruiz
Amelito M Torres
Karen R Kelly
Suellen M Curkendall
机构：
[1] Thomson Reuters Inc,Outcomes Research
[2] Bristol Myers Squibb,Global Health Economics and Outcomes Research
[3] Eli Lilly and Company,Global Health Outcomes: Endocrine/Obesity/Metabolism
[4] Lilly Technology Center,Outcomes Research
[5] Thomson Reuters Inc,Healthcare Research and Analytics
[6] GE Healthcare,Diabetes and Devices Platform
[7] Eli Lilly and Company,undefined
[8] Lilly Technology Center,undefined
来源：
BMC Endocrine Disorders | / 11卷
关键词：
Insulin Therapy; Human Insulin; Basal Insulin; Index Insulin; Mealtime Insulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal ± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts
    Giugliano, Dario
    Tracz, Mariusz
    Shah, Sanjiv
    Calle-Pascual, Alfonso
    Mistodie, Cristina
    Duarte, Rui
    Sari, Ramazan
    Woo, Vincent
    Jiletcovici, Alina O.
    Deinhard, Juergen
    Wille, Simone A.
    Kiljanski, Jacek
    DIABETES CARE, 2014, 37 (02) : 372 - 380
  • [32] INVESTIGATIONAL NEW INSULIN GLARGINE U300: GLYCAEMIC CONTROL AND HYPOGLYCAEMIA IN TYPE 2 DIABETES USING A MEALTIME plus BASAL INSULIN REGIMEN (EDITION I)
    Bolli, G. B.
    Home, P. D.
    Ziemen, M.
    Muehlen-Bartmer, I.
    Bizet, F.
    Riddle, M. C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 : A89 - A89
  • [33] COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRAN
    Davari, M.
    Khorasani, E.
    Shojaei, Savari R.
    Sari, Akbari A.
    Saiyarsarai, P.
    VALUE IN HEALTH, 2018, 21 : S129 - S130
  • [34] Efficacy of treatment with a basal-prandial insulin regimen in patients with type 2 diabetes mellitus previously treated with premixed insulin
    Javier Garcia-Soidan, Francisco
    AVANCES EN DIABETOLOGIA, 2013, 29 (01): : 12 - 18
  • [35] Glycaemic control with insulin glulisine versus regular human insulin in a basal-bolus regimen in patients with Type 2 diabetes
    Dailey, G
    Rosenstock, J
    Moses, R
    Ways, K
    DIABETOLOGIA, 2004, 47 : A265 - A266
  • [36] Glycemic control with insulin glulisine versus regular human insulin in a basal-bolus regimen in patients with type 2 diabetes
    Dailey, G
    Rosenstock, J
    Moses, R
    Ways, K
    DIABETES, 2004, 53 : A121 - A121
  • [37] Patient Reported Outcomes in Adults with Type 2 Diabetes Using Mealtime AFRESA™ (Inhaled Technosphere® Insulin) and Basal Insulin Versus Premixed Insulin
    Howard, Campbell P.
    Rubin, Richard R.
    Peyrot, Mark
    DIABETES, 2009, 58 : A148 - A148
  • [38] Predictors of Adherence and Persistence to Basal Insulin Therapy in Adults with Type 2 Diabetes
    Aroda, Vanita R.
    Nielsen, Nick F.
    Mangla, Kamal K.
    Wang, Yi
    Namvar, Tarlan
    Rajpura, Jigar R.
    DIABETES, 2023, 72
  • [39] Postprandial increase in IL 6 and TNFα is reduced by a basal plus prandial insulin regimen compared with a basal insulin regimen in type 2 diabetes (T2D) patients
    Tan, Meng H.
    Brown, W. Virgil
    Goldberg, Ronald B.
    Ceriello, Antonio
    Beisswenger, Paul J.
    Le, Ngoc-Anh
    Sarwat, Samiha
    Jones, Cate A.
    Milicevic, Zvonko
    Robbins, David C.
    DIABETES, 2007, 56 : A174 - A174
  • [40] Patient-Reported Outcomes in Adults with Type 2 Diabetes Using Mealtime Inhaled Technosphere Insulin and Basal Insulin Versus Premixed Insulin
    Peyrot, Mark
    Rubin, Richard R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2011, 13 (12) : 1201 - 1206
12345